256383-45-6 Usage
Description
4-Nonylphenylboronic acid, also known as Nonylbenzeneboronic acid, is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme responsible for hydrolyzing and deactivating anandamide. It also inhibits monoacylglycerol lipase (MAGL), which hydrolyzes 2-arachidonoyl glycerol (2-AG). With a CAS number of 256383-45-6, this compound has demonstrated its effectiveness in various applications due to its unique properties.
Uses
Used in Pharmaceutical Industry:
4-Nonylphenylboronic acid is used as an enzyme inhibitor for the treatment of various conditions related to FAAH and MAGL inhibition. Its potent and selective nature makes it a valuable compound in the development of new therapeutic approaches.
Used in Research Applications:
In the field of research, 4-Nonylphenylboronic acid serves as a valuable tool for studying the roles of FAAH and MAGL in various biological processes. By inhibiting these enzymes, researchers can gain insights into the mechanisms underlying their functions and potential therapeutic targets.
Used in Drug Development:
4-Nonylphenylboronic acid is used as a lead compound in the development of new drugs targeting FAAH and MAGL. Its potent inhibition of these enzymes can potentially lead to the creation of novel therapeutic agents for treating conditions related to their dysregulation.
Used in Neurological Applications:
Due to its ability to inhibit FAAH, which is involved in the degradation of anandamide, a neurotransmitter associated with the regulation of pain, mood, and appetite, 4-Nonylphenylboronic acid has potential applications in the treatment of neurological disorders such as chronic pain, anxiety, and depression.
in vitro
4-(n-nonyl) benzeneboronic acid was synthezed as a potent inhibitor of faah, with an ic50 of 9.1 nm. 4-(n-nonyl) benzeneboronic acid was also found to be able to inhibit magl, which could hydrolyze 2-arachidonoyl glycerol, but at around 1000-fold higher concentration. moreover, it was found that as the most potent para-substituted compound, 4-(n-nonyl) benzeneboronic acid showed rather high pka of 9.1. in addition, the molecular docking was utilized to gain insight on the faah binding mode of 4-(n-nonyl) benzeneboronic acid and a putative binding mode was observed [1].
IC 50
9.1 nm
References
1) Minkkila?et al.?(2008),?Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase; J. Med. Chem.,?51?7057
Check Digit Verification of cas no
The CAS Registry Mumber 256383-45-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,6,3,8 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 256383-45:
(8*2)+(7*5)+(6*6)+(5*3)+(4*8)+(3*3)+(2*4)+(1*5)=156
156 % 10 = 6
So 256383-45-6 is a valid CAS Registry Number.
InChI:InChI=1/C15H25BO2/c1-2-3-4-5-6-7-8-9-14-10-12-15(13-11-14)16(17)18/h10-13,17-18H,2-9H2,1H3
256383-45-6Relevant articles and documents
Design and synthesis of boronic acid inhibitors of endothelial lipase
O'Connell, Daniel P.,Leblanc, Daniel F.,Cromley, Debra,Billheimer, Jeffrey,Rader, Daniel J.,Bachovchin, William W.
, p. 1397 - 1401 (2012/03/26)
Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL.
